CBIO
Crescent Biopharma, Inc.$24.11-1.03 (-4.12%)Prev Close$25.15·MCap$683.4M·P/E1062.45·Vol55.3K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$0.00
●
Active Insiders
0
last 12 mo
CBIO Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Invus Public Equities, L.P. | Sell | 322,361 | $0.19 | $61.2K1.2% OS | 6,578,438 | |
| Aug 7, 2024 | Invus Public Equities, L.P. | Sell | 220,255 | $0.19 | $41.2K0.8% OS | 6,695,658 | |
| Aug 5, 2024 | Invus Public Equities, L.P. | Sell | 349,764 | $0.20 | $71.1K1.3% OS | 7,146,381 | |
| Jul 30, 2024 | Invus Public Equities, L.P. | Sell | 1,379,119 | $0.23 | $315.3K5.0% OS | 8,330,729 | |
| Jun 24, 2024 | Rock Edwin | Chief Medical Officer | Buy | 305,000 | $0.26 | $78.8K1.1% OS | 680,403+81% |
| Jun 20, 2024 | Hahn Brian M. | SVP Finance, CFO | Buy | 17,500 | $0.25 | $4.3K | 70,643+33% |
| Sep 25, 2023 | Rock Edwin | Chief Medical Officer | Buy | 65,403 | $1.38 | $90.3K | 375,403 |
| May 18, 2023 | Hahn Brian M. | SVP Finance, CFO | Sell | 3,700 | $1.95 | $7.2K | 53,143 |
| May 11, 2023 | JUNIUS DANIEL M | Director | Buy | 30,000 | $1.56 | $46.8K | 93,250+47% |
| May 9, 2023 | Johnson Bruce S | SVP & Chief Commercial Officer | Buy | 13,500 | $1.57 | $21.2K | 138,980 |
| Feb 28, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 100,000 | $1.70 | $170.0K | 8,589,064 |
| Feb 23, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 400,000 | $1.78 | $712.3K1.5% OS | 8,489,064 |
| Feb 17, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 1,515,266 | $2.00 | $3.03M5.5% OS | 8,089,064 |
| Feb 13, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 11,451 | $3.24 | $37.1K | 6,573,798 |
| Jan 27, 2023 | SANDELL SCOTT D | 10% Owner | Sell | 3,652,016 | $3.14 | $11.48M13.3% OS | 4,379,242-45% |
| Jan 6, 2023 | SANDELL SCOTT D | 10% Owner | Sell | 71,362 | $2.76 | $196.9K | 4,737,613 |
| Jan 4, 2023 | SANDELL SCOTT D | 10% Owner | Sell | 398,133 | $2.98 | $1.19M1.4% OS | 4,928,974 |
| Dec 27, 2022 | Rock Edwin | Chief Medical Officer | Buy | 110,000 | $2.25 | $247.5K | 310,000+55% |
| Nov 18, 2022 | JUNIUS DANIEL M | Director | Buy | 20,000 | $1.87 | $37.4K | 63,250+46% |
| Nov 16, 2022 | Rock Edwin | Chief Medical Officer | Buy | 200,000 | $1.55 | $309.0K0.7% OS | 200,000 |
| Nov 14, 2022 | Girard Armand | SVP, Chief Business Officer | Buy | 6,500 | $1.05 | $6.8K | 29,161+29% |
| Nov 14, 2022 | Hahn Brian M. | SVP Finance, CFO | Buy | 20,000 | $1.06 | $21.2K | 56,843+54% |
| Nov 14, 2022 | Magnani John L. | SVP of Research, CSO | Buy | 45,045 | $1.17 | $52.7K | 366,078 |
| Nov 14, 2022 | PEARSON TIMOTHY R | Director | Buy | 19,400 | $1.29 | $25.0K | 24,650+370% |
| Nov 14, 2022 | Semerjian Harout | Chief Executive Officer | Buy | 25,000 | $1.29 | $32.3K | 25,000 |
| Mar 10, 2022 | Girard Armand | SVP, Chief Business Officer | Sell | 2,339 | $1.09 | $2.5K | 22,661 |
| Mar 10, 2022 | Hahn Brian M. | SVP Finance, CFO | Sell | 2,917 | $1.09 | $3.2K | 36,843 |
| Mar 10, 2022 | Magnani John L. | SVP of Research, CSO | Sell | 3,227 | $1.09 | $3.5K | 321,033 |
| Nov 18, 2021 | Andrews Patricia S | Director | Buy | 40,000 | $2.05 | $82.0K | 45,250+762% |
CBIO Insider Buying Activity
The following table shows recent insider purchases of Crescent Biopharma, Inc. (CBIO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 24, 2024 | Rock Edwin | Chief Medical Officer | Buy | 305,000 | $0.26 | $78.8K1.1% OS | 680,403+81% |
| Jun 20, 2024 | Hahn Brian M. | SVP Finance, CFO | Buy | 17,500 | $0.25 | $4.3K | 70,643+33% |
| Sep 25, 2023 | Rock Edwin | Chief Medical Officer | Buy | 65,403 | $1.38 | $90.3K | 375,403 |
| May 11, 2023 | JUNIUS DANIEL M | Director | Buy | 30,000 | $1.56 | $46.8K | 93,250+47% |
| May 9, 2023 | Johnson Bruce S | SVP & Chief Commercial Officer | Buy | 13,500 | $1.57 | $21.2K | 138,980 |
| Feb 28, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 100,000 | $1.70 | $170.0K | 8,589,064 |
| Feb 23, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 400,000 | $1.78 | $712.3K1.5% OS | 8,489,064 |
| Feb 17, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 1,515,266 | $2.00 | $3.03M5.5% OS | 8,089,064 |
| Feb 13, 2023 | Invus Public Equities, L.P. | 10% Owner | Buy | 11,451 | $3.24 | $37.1K | 6,573,798 |
| Dec 27, 2022 | Rock Edwin | Chief Medical Officer | Buy | 110,000 | $2.25 | $247.5K | 310,000+55% |
| Nov 18, 2022 | JUNIUS DANIEL M | Director | Buy | 20,000 | $1.87 | $37.4K | 63,250+46% |
| Nov 16, 2022 | Rock Edwin | Chief Medical Officer | Buy | 200,000 | $1.55 | $309.0K0.7% OS | 200,000 |
| Nov 14, 2022 | Girard Armand | SVP, Chief Business Officer | Buy | 6,500 | $1.05 | $6.8K | 29,161+29% |
| Nov 14, 2022 | Hahn Brian M. | SVP Finance, CFO | Buy | 20,000 | $1.06 | $21.2K | 56,843+54% |
| Nov 14, 2022 | Magnani John L. | SVP of Research, CSO | Buy | 45,045 | $1.17 | $52.7K | 366,078 |
| Nov 14, 2022 | PEARSON TIMOTHY R | Director | Buy | 19,400 | $1.29 | $25.0K | 24,650+370% |
| Nov 14, 2022 | Semerjian Harout | Chief Executive Officer | Buy | 25,000 | $1.29 | $32.3K | 25,000 |
| Nov 18, 2021 | Andrews Patricia S | Director | Buy | 40,000 | $2.05 | $82.0K | 45,250+762% |
CBIO Insider Selling Activity
The following table shows recent insider sales of Crescent Biopharma, Inc. (CBIO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Invus Public Equities, L.P. | Sell | 322,361 | $0.19 | $61.2K1.2% OS | 6,578,438 | |
| Aug 7, 2024 | Invus Public Equities, L.P. | Sell | 220,255 | $0.19 | $41.2K0.8% OS | 6,695,658 | |
| Aug 5, 2024 | Invus Public Equities, L.P. | Sell | 349,764 | $0.20 | $71.1K1.3% OS | 7,146,381 | |
| Jul 30, 2024 | Invus Public Equities, L.P. | Sell | 1,379,119 | $0.23 | $315.3K5.0% OS | 8,330,729 | |
| May 18, 2023 | Hahn Brian M. | SVP Finance, CFO | Sell | 3,700 | $1.95 | $7.2K | 53,143 |
| Jan 27, 2023 | SANDELL SCOTT D | 10% Owner | Sell | 3,652,016 | $3.14 | $11.48M13.3% OS | 4,379,242-45% |
| Jan 6, 2023 | SANDELL SCOTT D | 10% Owner | Sell | 71,362 | $2.76 | $196.9K | 4,737,613 |
| Jan 4, 2023 | SANDELL SCOTT D | 10% Owner | Sell | 398,133 | $2.98 | $1.19M1.4% OS | 4,928,974 |
| Mar 10, 2022 | Girard Armand | SVP, Chief Business Officer | Sell | 2,339 | $1.09 | $2.5K | 22,661 |
| Mar 10, 2022 | Hahn Brian M. | SVP Finance, CFO | Sell | 2,917 | $1.09 | $3.2K | 36,843 |
| Mar 10, 2022 | Magnani John L. | SVP of Research, CSO | Sell | 3,227 | $1.09 | $3.5K | 321,033 |
CBIO Insiders
Similar Stocks to CBIO
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B